Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Paula M. Ladwig"'
Autor:
Paula M. Ladwig, Ann L. Rivard, Alex Barbeln, Anthony Maus, David L. Murray, Melissa R. Snyder, Maria A.V. Willrich
Publikováno v:
Journal of Mass Spectrometry and Advances in the Clinical Lab, Vol 32, Iss , Pp 24-30 (2024)
Introduction: Therapeutic drug monitoring of infliximab has become the standard of care for inflammatory bowel disease in the setting of loss of response to therapy, and occasionally in proactive therapy personalization. Measurement of infliximab by
Externí odkaz:
https://doaj.org/article/eca8d07ac2a540d78f474e928cb0c67d
Autor:
Paula M. Ladwig, Maria A.V. Willrich
Publikováno v:
Journal of Mass Spectrometry and Advances in the Clinical Lab, Vol 21, Iss , Pp 10-18 (2021)
Introduction: Ravulizumab (RAVUL) is a new complement inhibitor, with a difference of 4 amino acids in the heavy chain from a predecessor compound, eculizumab (ECUL). Objectives: First, to utilize mass spectrometry (MS) to characterize RAVUL and veri
Externí odkaz:
https://doaj.org/article/904a3082fd114fb78d3295830b4aa6bc
Autor:
Paula M Ladwig, Jeffrey E Vaks
Publikováno v:
The Journal of Applied Laboratory Medicine. 7:815-817
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e5d0dfcf2c7810fd068b81a7b425198
https://doi.org/10.1093/jalm/jfac007
https://doi.org/10.1093/jalm/jfac007
Autor:
Ira D Miller, Mindy C. Kohlhagen, Paula M. Ladwig, Surendra Dasari, Shaji Kumar, Angela Dispenzieri, Maria Alice V. Willrich, David L. Murray
Publikováno v:
Clinical biochemistry.
Monoclonal gammopathy of undetermined significance (MGUS) patients with M-proteins containing n-glycosylated light chains (GLC) have an increased risk for progression to symptomatic plasma cell disorders (PCD). Large-scale research involving the dete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba5e91531f5b93d014315cdf2a8d3e75
https://pubmed.ncbi.nlm.nih.gov/36113628
https://pubmed.ncbi.nlm.nih.gov/36113628
Autor:
Mindy C. Kohlhagen, Julie I. Tange, Rachel Leger, David L. Murray, Paula M. Ladwig, Abdulrahman Saadalla, Jansen Seheult, Aneel A. Ashrani
Publikováno v:
Blood. 136:1988-1992
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::277dc08deed88266f61ae8748074545e
https://doi.org/10.1182/blood.2020005604
https://doi.org/10.1182/blood.2020005604
Autor:
Kendall W. Cradic, Ann L Rivard, Karl Florian Wintgens, Maria Alice V. Willrich, Waddah Katrangi, Paula M. Ladwig
Publikováno v:
Clinical Chemistry and Laboratory Medicine (CCLM). 58:864-872
Background While quantitation methods for small-molecule and tryptic peptide bottom-up mass spectrometry (MS) have been well defined, quantitation methods for top-down or middle-up MS approaches have not been as well defined. Therapeutic monoclonal a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5305acf3e1eaacfeeac2fda42ce6da5
https://doi.org/10.1515/cclm-2019-0862
https://doi.org/10.1515/cclm-2019-0862
Autor:
Robert A. Kyle, Angela Dispenzieri, Paula M. Ladwig, John A. Lust, Melissa R. Snyder, David L. Murray, Maria Alice V. Willrich, Taxiarchis Kourelis, Mark A Martinez, Mindy C. Kohlhagen, Erica M. Fatica, Josiah D Murray
Publikováno v:
Clinical biochemistry. 97
Background Plasma cell disorders (PCDs) are typically characterized by excessive production of a single immunoglobulin, defined as a monoclonal protein (M−protein). Some patients have more than one identifiable M−protein, termed biclonal. Traditi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e47e34ae0dcb9224c20fd8bf4e3c155e
https://pubmed.ncbi.nlm.nih.gov/34384797
https://pubmed.ncbi.nlm.nih.gov/34384797
Autor:
Meera Sridharan, Ronald S. Go, Paula M. Ladwig, Mark A Martinez, Maria Alice V. Willrich, David L. Murray
Publikováno v:
Journal of Immunological Methods. 490:112944
Ravulizumab is a new C5 inhibitor therapeutic monoclonal antibody with a longer half-life than eculizumab. Monitoring complete complement blockade by eculizumab has allowed personalized therapy in specific settings. Similar action is expected with ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::329a5ffcca4537955bbfd015820a00f3
https://doi.org/10.1016/j.jim.2020.112944
https://doi.org/10.1016/j.jim.2020.112944
Autor:
Ryan N. Olson, Bruna D. Andreguetto, Meera Sridharan, Me Lea D. Hetrick, Ann M. Rivard, Paula M. Ladwig, David L. Murray, Maria Alice V. Willrich, Fernando C. Fervenza, Sandra C. Bryant, Melissa R. Snyder, Linda J. Tostrud
Publikováno v:
Journal of immunological methods. 460
Eculizumab (ECU) blocks complement C5 cleavage, preventing the formation of C5a and the cytolytic effects of the membrane attack complex. The presence of ECU in blood impacts routine complement tests used to monitor treatment.Residual serum samples w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ff3f68b1b4657bbbaadd401945fd5c8
https://pubmed.ncbi.nlm.nih.gov/29935209
https://pubmed.ncbi.nlm.nih.gov/29935209
Autor:
Paula M. Ladwig, David L. Murray, Maria Alice V. Willrich, Melissa R. Snyder, David R. Barnidge
Publikováno v:
International Immunopharmacology. 28:513-520
Although therapeutic concentrations of infliximab (chimeric IgG1 kappa) are associated with improved clinical prognosis, clinical laboratory methods for monitoring are limited. Therefore, we aimed to develop a LC-MS/MS method to measure infliximab in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e43eb21c38c11bc5c4fd58d9c9811232
https://doi.org/10.1016/j.intimp.2015.07.007
https://doi.org/10.1016/j.intimp.2015.07.007